DXCM DexCom
- 125.880
- -1.510-1.19%
- 126.410
- +0.530+0.42%
DexCom News
Can DexCom, Inc.'s (NASDAQ:DXCM) ROE Continue To Surpass The Industry Average?
Here Is Why Growth Investors Should Buy DexCom (DXCM) Now
Ecolab (ECL) Q1 Earnings Surpass Estimates, Margins Rise
Here's How Much $1000 Invested In DexCom 15 Years Ago Would Be Worth Today
DexCom (NASDAQ:DXCM) has outperformed the market over the past 15 years by 25.99% on an annualized basis producing an average annual return of 38.03%. Currently, DexCom has a market capitalization of
Analysts Offer Insights on Healthcare Companies: AptarGroup (ATR), Dexcom (DXCM) and Aldeyra Therapeutics (ALDX)
Top 50 Stocks With the Highest Sensitivity to Interest Rates Changes - GS
DexCom, Insulet, Tandem Seen Benefitting the Most in Diabetes Survey - Wells Fargo
Stocks on Sale Today: Intel, Dexcom, Old Dominion, and More
Analysts Offer Insights on Healthcare Companies: Dexcom (DXCM), OptimizeRx (OPRX) and AbbVie (ABBV)
DexCom First Quarter 2024 Earnings: Beats Expectations
US stocks closed | PCE suspends inflation concerns, Google's performance soared more than 10% after that, and Nvidia rose more than 6%
The S&P Index rose 2.67% this week, and the NASDAQ rose 4.23%, all of which recorded the biggest weekly gain since November last year; the China General Index rose nearly 9% weekly, the biggest increase since July last year.
ABT, DHR, DXCM: Which "Strong Buy" Healthcare Stock Has More Upside?
The healthcare scene is home to some pretty defensive companies that aren’t exactly shying away from medical innovation.
Raymond James Adjusts DexCom Price Target to $160 From $151
DexCom (DXCM) has an average rating of Buy and price targets ranging from $105 to $170, according to analysts polled by Capital IQ. Price: 129.28, Change: -8.73, Percent Change: -6.33
DexCom Is Maintained at Buy by Canaccord Genuity
DexCom Is Maintained at Buy by Canaccord Genuity
Canadian Investment Banking Group: Maintaining the DexCom (DXCM.US) rating, adjusted from buy to buy rating, and adjusted the target price from $144.00 to $145.00.
Canadian Investment Banking Group: Maintaining the DexCom (DXCM.US) rating, adjusted from buy to buy rating, and adjusted the target price from $144.00 to $145.00.
Canaccord Genuity Maintains Buy on DexCom, Raises Price Target to $145
Canaccord Genuity analyst William Plovanic maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target from $144 to $145.
DexCom Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/26/2024 10.27% Canaccord Genuity $144 → $145 Maintains Buy 04/10/2024 23.95% UBS $153 → $163 Maintains
Why Alphabet Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
Shares of Alphabet Inc. (NASDAQ:GOOGL) (NASDAQ:GOOG) rose sharply in today's pre-market trading the company posted upbeat results for its first quarter.Google parent Alphabet said its first-quarter re
Dexcom (DXCM) Gets a Buy From Stifel Nicolaus
Earnings Call Summary | DexCom(DXCM.US) Q1 2024 Earnings Conference
The following is a summary of the DexCom, Inc. (DXCM) Q1 2024 Earnings Call Transcript:Financial Performance:DexCom reported revenue growth of 25% in Q1 2024, contributing to a total worldwide revenue
Analysis
Price Target
No Data
